



Clinical trial results:

A PHASE 1/2 OPEN LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ZN-C5 ALONE AND IN COMBINATION WITH PALBOCICLIB IN SUBJECTS WITH ESTROGEN-RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 NEGATIVE ADVANCED BREAST CANCER

Summary

EudraCT number	2018-001364-27
Trial protocol	CZ LT BG HU
Global end of trial date	22 December 2022

Results information

Result version number	v2 (current)
This version publication date	29 August 2024
First version publication date	02 May 2024
Version creation reason	• Correction of full data set Consistent with CT.gov posting.

Trial information

Trial identification

Sponsor protocol code	ZN-c5-001
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03560531
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Zeno Alpha Inc.
Sponsor organisation address	10275 Science Center Drive, Suite 200, San Diego, California, United States,
Public contact	Regulatory Head, Zeno Alpha, Inc., , +1 (858) 263-4333, RegLeads@zentalis.com
Scientific contact	Head of Regulatory, Zeno Alpha, Inc., , +1 (858) 263-4333, RegLeads@zentalis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 December 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 April 2022
Global end of trial reached?	Yes
Global end of trial date	22 December 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Phase 1

- Monotherapy Dose Escalation: Determine a maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for ZN-c5 as a monotherapy
- Monotherapy Expansion: Investigate the safety and tolerability of ZN-c5 as a monotherapy in subjects with Estrogen Receptor (ER) positive, Human Epidermal Growth Factor Receptor-2 (HER2) negative advanced breast cancer
- Combination Dose Escalation: Determine an MTD or RP2D for ZN-c5 when administered in combination with palbociclib Phase 2
- Monotherapy Phase 2: Determine preliminary anti-tumor efficacy [Clinical Benefit Rate (CBR)] for ZN-c5 as a monotherapy
- Combination Phase 2: Determine preliminary anti-tumor efficacy (CBR) for ZN-c5 when administered in combination with palbociclib

Protection of trial subjects:

This study was conducted in accordance with the ethical principles of Good Clinical Practice, according to the International Conference on Harmonization Guidelines.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 November 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 109
Country: Number of subjects enrolled	European Union: 72
Worldwide total number of subjects	181
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	105
From 65 to 84 years	74
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

Study was initiated on 30 November 2018 and completed on 22 December 2022 (last participant last visit). 29 centers in Belarus, Bosnia and Herzegovina, the Czech Republic, Hungary, Lithuania, Russia, Serbia, Ukraine, and the United States enrolled the participants.

Pre-assignment

Screening details:

Subjects received study drug once daily for 28-days cycle. At the same time some subjects could also receive the study drug twice daily. The study also has End-of-Treatment visit; 30 day safety follow up and disease assessment and long term follow up for every 12 weeks.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Phase 1 (Monotherapy): ZN-c5 50 mg QD

Arm description:

Participants who received ZN-c5 50 mg once daily (QD) in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Arm title	Phase 1 (Monotherapy): ZN-c5 75 mg QD
------------------	---------------------------------------

Arm description:

Participants who received ZN-c5 75 mg QD in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Arm title	Phase 1 (Monotherapy): ZN-c5 100 mg QD
------------------	--

Arm description:

Participants who received ZN-c5 100 mg QD in Phase 1 were included in this arm.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.	
Arm title	Phase 1 (Monotherapy): ZN-c5 75 mg BID
Arm description:	
Participants who received ZN-c5 75 mg twice daily (BID) in Phase 1 were included in this arm.	
Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.	
Arm title	Phase 1 (Monotherapy): ZN-c5 150 mg QD
Arm description:	
Participants who received ZN-c5 150 mg QD in Phase 1 were included in this arm.	
Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.	
Arm title	Phase 1 (Monotherapy): ZN-c5 150 mg BID
Arm description:	
Participants who received ZN-c5 150 mg BID in Phase 1 were included in this arm.	
Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.	
Arm title	Phase 1 (Monotherapy): ZN-c5 300 mg QD
Arm description:	
Participants who received ZN-c5 300 mg QD in Phase 1 were included in this arm.	
Arm type	Experimental

Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Arm title	Phase 2 (Monotherapy): ZN-c5 50 mg QD
------------------	---------------------------------------

Arm description:

Participants who received ZN-c5 50 mg QD in Phase 2 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Arm title	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
------------------	---

Arm description:

Participants who received ZN-c5 25 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Investigational medicinal product name	Palbociclib
Investigational medicinal product code	
Other name	IBRANCE®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Palbociclib was dosed orally at 125 mg QD for 21 consecutive days, followed by 7 days off treatment to comprise a complete cycle of 28 days.

Arm title	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib
------------------	--

Arm description:

Participants who received ZN-c5 25 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts

and a Phase 2 cohort.

Investigational medicinal product name	Palbociclib
Investigational medicinal product code	
Other name	IBRANCE®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Palbociclib was dosed orally at 125 mg QD for 21 consecutive days, followed by 7 days off treatment to comprise a complete cycle of 28 days.

Arm title	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib
------------------	---

Arm description:

Participants who received ZN-c5 50 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Investigational medicinal product name	Palbociclib
Investigational medicinal product code	
Other name	IBRANCE®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Palbociclib was dosed orally at 125 mg QD for 21 consecutive days, followed by 7 days off treatment to comprise a complete cycle of 28 days.

Arm title	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
------------------	--

Arm description:

Participants who received ZN-c5 50 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Investigational medicinal product name	Palbociclib
Investigational medicinal product code	
Other name	IBRANCE®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Palbociclib was dosed orally at 125 mg QD for 21 consecutive days, followed by 7 days off treatment to comprise a complete cycle of 28 days.

Arm title	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib
------------------	--

Arm description:

Participants who received ZN-c5 100 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Investigational medicinal product name	Palbociclib
Investigational medicinal product code	
Other name	IBRANCE®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Palbociclib was dosed orally at 125 mg QD for 21 consecutive days, followed by 7 days off treatment to comprise a complete cycle of 28 days.

Arm title	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib
------------------	--

Arm description:

Participants who received ZN-c5 150 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Arm type	Experimental
Investigational medicinal product name	ZN-c5
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose escalation cohorts are planned to determine MTD or RP2D of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.

Investigational medicinal product name	Palbociclib
Investigational medicinal product code	
Other name	IBRANCE®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Palbociclib was dosed orally at 125 mg QD for 21 consecutive days, followed by 7 days off treatment to comprise a complete cycle of 28 days.

Number of subjects in period 1	Phase 1 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Monotherapy): ZN- c5 75 mg QD	Phase 1 (Monotherapy): ZN- c5 100 mg QD
Started	16	3	3
Completed	0	0	0
Not completed	16	3	3
Study end per-protocol	1	1	2
Consent withdrawn by subject	1	-	-

Death	4	1	1
Early study termination by sponsor	9	-	-
Lost to follow-up	1	1	-

Number of subjects in period 1	Phase 1 (Monotherapy): ZN- c5 75 mg BID	Phase 1 (Monotherapy): ZN- c5 150 mg QD	Phase 1 (Monotherapy): ZN- c5 150 mg BID
Started	6	15	3
Completed	0	0	0
Not completed	6	15	3
Study end per-protocol	-	1	-
Consent withdrawn by subject	-	-	-
Death	2	6	1
Early study termination by sponsor	4	8	2
Lost to follow-up	-	-	-

Number of subjects in period 1	Phase 1 (Monotherapy): ZN- c5 300 mg QD	Phase 2 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
Started	10	75	10
Completed	0	0	0
Not completed	10	75	10
Study end per-protocol	-	-	-
Consent withdrawn by subject	-	3	2
Death	4	8	1
Early study termination by sponsor	5	64	7
Lost to follow-up	1	-	-

Number of subjects in period 1	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
Started	5	18	2
Completed	0	0	0
Not completed	5	18	2
Study end per-protocol	-	-	-
Consent withdrawn by subject	-	-	-
Death	3	2	-
Early study termination by sponsor	2	16	2
Lost to follow-up	-	-	-

Number of subjects in period 1	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib
Started	12	3

Completed	0	0
Not completed	12	3
Study end per-protocol	-	-
Consent withdrawn by subject	2	-
Death	4	1
Early study termination by sponsor	6	2
Lost to follow-up	-	-

Baseline characteristics

Reporting groups

Reporting group title	Phase 1 (Monotherapy): ZN-c5 50 mg QD
Reporting group description: Participants who received ZN-c5 50 mg once daily (QD) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 75 mg QD
Reporting group description: Participants who received ZN-c5 75 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 100 mg QD
Reporting group description: Participants who received ZN-c5 100 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 75 mg BID
Reporting group description: Participants who received ZN-c5 75 mg twice daily (BID) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 150 mg QD
Reporting group description: Participants who received ZN-c5 150 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 150 mg BID
Reporting group description: Participants who received ZN-c5 150 mg BID in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 300 mg QD
Reporting group description: Participants who received ZN-c5 300 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 2 (Monotherapy): ZN-c5 50 mg QD
Reporting group description: Participants who received ZN-c5 50 mg QD in Phase 2 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 25 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib
Reporting group description: Participants who received ZN-c5 25 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 50 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
Reporting group description: Participants who received ZN-c5 50 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 100 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 150 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	

Reporting group values	Phase 1 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Monotherapy): ZN- c5 75 mg QD	Phase 1 (Monotherapy): ZN- c5 100 mg QD
Number of subjects	16	3	3
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	11	3	3
From 65-84 years	5	0	0
85 years and over	0	0	0
Gender categorical Units: Subjects			
Female	16	3	3
Male	0	0	0
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	0	0
White	12	3	3
More than one race	0	0	0
Unknown or Not Reported	1	0	0
Region of Enrollment Units: Subjects			
United States	8	3	3
Europe	8	0	0

Reporting group values	Phase 1 (Monotherapy): ZN- c5 75 mg BID	Phase 1 (Monotherapy): ZN- c5 150 mg QD	Phase 1 (Monotherapy): ZN- c5 150 mg BID
Number of subjects	6	15	3
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	10	2
From 65-84 years	3	5	1

85 years and over	0	0	0
-------------------	---	---	---

Gender categorical Units: Subjects			
Female	6	15	3
Male	0	0	0
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	1	0
White	5	12	3
More than one race	0	0	0
Unknown or Not Reported	0	2	0
Region of Enrollment Units: Subjects			
United States	6	15	3
Europe	0	0	0

Reporting group values	Phase 1 (Monotherapy): ZN- c5 300 mg QD	Phase 2 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
Number of subjects	10	75	10
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	5	39	6
From 65-84 years	4	35	4
85 years and over	1	1	0
Gender categorical Units: Subjects			
Female	10	75	10
Male	0	0	0
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	1
Black or African American	0	0	1
White	9	74	8
More than one race	0	0	0

Unknown or Not Reported	1	1	0
Region of Enrollment Units: Subjects			
United States	8	13	10
Europe	2	62	0

Reporting group values	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
Number of subjects	5	18	2
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	8	2
From 65-84 years	2	10	0
85 years and over	0	0	0
Gender categorical Units: Subjects			
Female	5	18	2
Male	0	0	0
Race Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	5	17	1
More than one race	0	0	0
Unknown or Not Reported	0	1	0
Region of Enrollment Units: Subjects			
United States	5	18	2
Europe	0	0	0

Reporting group values	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib	Total
Number of subjects	12	3	181
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0

Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	8	2	105
From 65-84 years	4	1	74
85 years and over	0	0	2
Gender categorical			
Units: Subjects			
Female	11	3	180
Male	1	0	1
Race			
Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	0	0	3
Native Hawaiian or Other Pacific Islander	0	0	1
Black or African American	2	0	5
White	10	3	165
More than one race	0	0	0
Unknown or Not Reported	0	0	6
Region of Enrollment			
Units: Subjects			
United States	12	3	109
Europe	0	0	72

End points

End points reporting groups

Reporting group title	Phase 1 (Monotherapy): ZN-c5 50 mg QD
Reporting group description: Participants who received ZN-c5 50 mg once daily (QD) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 75 mg QD
Reporting group description: Participants who received ZN-c5 75 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 100 mg QD
Reporting group description: Participants who received ZN-c5 100 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 75 mg BID
Reporting group description: Participants who received ZN-c5 75 mg twice daily (BID) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 150 mg QD
Reporting group description: Participants who received ZN-c5 150 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 150 mg BID
Reporting group description: Participants who received ZN-c5 150 mg BID in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Monotherapy): ZN-c5 300 mg QD
Reporting group description: Participants who received ZN-c5 300 mg QD in Phase 1 were included in this arm.	
Reporting group title	Phase 2 (Monotherapy): ZN-c5 50 mg QD
Reporting group description: Participants who received ZN-c5 50 mg QD in Phase 2 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 25 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib
Reporting group description: Participants who received ZN-c5 25 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 50 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
Reporting group description: Participants who received ZN-c5 50 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 100 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib
Reporting group description: Participants who received ZN-c5 150 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	

Primary: Clinical Benefit Rate for ZN-c5 as a Monotherapy

End point title	Clinical Benefit Rate for ZN-c5 as a Monotherapy ^{[1][2]}
-----------------	--

End point description:

CBR is defined as the number of participants who have at least one confirmed response of complete response (CR) or partial response (PR) (only if participant has measurable disease), or stable disease (SD) ≥ 24 weeks (or non- CR/non-progressive disease (PD) ≥ 24 weeks for participants with non-measurable disease) prior to any evidence of progression. Full Analysis Set consisted of all participants who received ≥ 1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Primary
----------------	---------

End point timeframe:

24 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistical analysis was performed for the primary end point.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: Participants	7	0	1	1

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: Participants	4	1	5	38

Statistical analyses

No statistical analyses for this end point

Primary: Best Overall Response (BOR) for ZN-c5 as a Monotherapy

End point title	Best Overall Response (BOR) for ZN-c5 as a Monotherapy ^{[3][4]}
-----------------	--

End point description:

Best overall response was summarized categorically based on the four RECIST categories: CR, PR, SD and PD. Full Analysis Set consisted of all participants who received ≥ 1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Primary
----------------	---------

End point timeframe:

24 Weeks

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistical analysis was performed for the primary end point.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: Participants				
CR	0	0	0	0
PR	0	0	0	0
SD	13	1	1	6
SD ≥24 weeks	7	0	1	1
8 weeks < SD <24 weeks	6	1	0	5
PD	3	2	2	0
Non-Responders (NR)	0	0	0	0
Not Evaluable (NE)	0	0	0	0

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: Participants				
CR	0	0	0	0
PR	1	0	1	3
SD	10	3	7	50
SD ≥24 weeks	3	1	4	35
8 weeks < SD <24 weeks	7	2	3	15
PD	4	0	1	19
Non-Responders (NR)	0	0	1	3
Not Evaluable (NE)	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Progression-Free Survival (PFS) at 2 Months

End point title	Monotherapy Only: Percentage of Participants With
-----------------	---

End point description:

PFS is defined as the time (in months) from the date of first dosing until the date of objective PD (as defined by RECIST version 1.1) or death (by any cause in the absence of progression), whichever occurs earlier. Kaplan-Meier estimates at 2 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. The Tumor Response-Evaluable Set includes all participants in the full analysis set with at least 1 evaluable postbaseline response assessment using RECIST 1.1.

End point type	Secondary
----------------	-----------

End point timeframe:

2 months

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: percentage of participants				
number (confidence interval 95%)	87.1 (57.3 to 96.6)	66.7 (5.4 to 94.5)	33.3 (0.9 to 77.4)	100.0 (100.0 to 100.0)

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	9	72
Units: percentage of participants				
number (confidence interval 95%)	73.3 (43.6 to 89.1)	100.0 (100.0 to 100.0)	87.5 (38.7 to 98.1)	77.8 (66.3 to 85.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Progression-Free Survival at 4 Months

End point title	Monotherapy Only: Percentage of Participants With Progression-Free Survival at 4 Months ^[6]
-----------------	--

End point description:

PFS is defined as the time (in months) from the date of first dosing until the date of objective PD (as defined by RECIST version 1.1) or death (by any cause in the absence of progression), whichever occurs earlier. Kaplan-Meier estimates at 4 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. The Tumor Response-Evaluable Set includes all participants in the full analysis set with at least 1 evaluable postbaseline response assessment using RECIST 1.1. Only participants with data collected at Month 4 are reported.

End point type	Secondary
----------------	-----------

End point timeframe:

4 months

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	0 ^[7]	3	6
Units: percentage of participants				
number (confidence interval 95%)	73.7 (44.1 to 89.2)	(to)	33.3 (0.9 to 77.4)	33.3 (4.6 to 67.6)

Notes:

[7] - No participants analyzed.

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	9	72
Units: percentage of participants				
number (confidence interval 95%)	50.3 (22.6 to 72.8)	100.0 (100.0 to 100.0)	62.5 (22.9 to 86.1)	60.8 (48.5 to 71.0)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Progression-Free Survival at 6 Months

End point title	Monotherapy Only: Percentage of Participants With Progression-Free Survival at 6 Months ^[8]
-----------------	--

End point description:

PFS is defined as the time (in months) from the date of first dosing until the date of objective PD (as defined by RECIST version 1.1) or death (by any cause in the absence of progression), whichever occurs earlier. Kaplan-Meier estimates at 6 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. The Tumor Response-Evaluable Set includes all participants in the full analysis set with at least 1 evaluable postbaseline response assessment using RECIST 1.1. Only participants with data collected at Month 6 are reported.

End point type	Secondary
----------------	-----------

End point timeframe:

6 months

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	0 ^[9]	3	6
Units: percentage of participants				
number (confidence interval 95%)	64.5 (33.6 to 83.8)	(to)	33.3 (0.9 to 77.4)	16.7 (0.8 to 51.7)

Notes:

[9] - No participants analyzed.

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	9	72
Units: percentage of participants				
number (confidence interval 95%)	33.5 (10.8 to 58.4)	66.7 (5.4 to 94.5)	50.0 (15.2 to 77.5)	50.3 (38.1 to 61.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Progression-Free Survival at 8 Months

End point title	Monotherapy Only: Percentage of Participants With Progression-Free Survival at 8 Months ^[10]
-----------------	---

End point description:

PFS is defined as the time (in months) from the date of first dosing until the date of objective PD (as defined by RECIST version 1.1) or death (by any cause in the absence of progression), whichever occurs earlier. Kaplan-Meier estimates at 8 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. The Tumor Response-Evaluable Set includes all participants in the full analysis set with at least 1 evaluable postbaseline response assessment using RECIST 1.1. Only participants with data collected at Month 8 are reported. -9999 and 9999= The 95% confidence interval data was not determined as no participants with PFS at Month 8.

End point type	Secondary
----------------	-----------

End point timeframe:

8 months

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	0 ^[11]	3	6
Units: percentage of participants				
number (confidence interval 95%)	64.5 (33.6 to 83.8)	(to)	0.0 (-9999 to 9999)	16.7 (0.8 to 51.7)

Notes:

[11] - No participants analyzed.

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	9	72
Units: percentage of participants				
number (confidence interval 95%)	16.8 (2.7 to 41.2)	66.7 (5.4 to 94.5)	37.5 (8.7 to 67.4)	44.2 (32.3 to 55.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Progression-Free Survival at 10 Months

End point title	Monotherapy Only: Percentage of Participants With Progression-Free Survival at 10 Months ^[12]
-----------------	--

End point description:

PFS is defined as the time (in months) from the date of first dosing until the date of objective PD (as defined by RECIST version 1.1) or death (by any cause in the absence of progression), whichever occurs earlier. Kaplan-Meier estimates at 10 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. The Tumor Response-Evaluable Set includes all participants in the full analysis set with at least 1 evaluable postbaseline response assessment using RECIST 1.1. Only participants with data collected at Month 10 are reported. -9999 and 9999= The 95% confidence interval data was not determined as no participants with PFS at Month 10.

End point type	Secondary
----------------	-----------

End point timeframe:

10 months

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	0 ^[13]	3	6
Units: percentage of participants				
number (confidence interval 95%)	55.2 (25.2 to 77.5)	(to)	0.0 (-9999 to 9999)	16.7 (0.8 to 51.7)

Notes:

[13] - No participants analyzed.

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	9	72
Units: percentage of participants				
number (confidence interval 95%)	16.8 (2.7 to 41.2)	0.0 (-9999 to 9999)	12.5 (0.7 to 42.3)	35.9 (24.6 to 47.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Progression-Free Survival at 12 Months

End point title	Monotherapy Only: Percentage of Participants With Progression-Free Survival at 12 Months ^[14]
-----------------	--

End point description:

PFS is defined as the time (in months) from the date of first dosing until the date of objective PD (as defined by RECIST version 1.1) or death (by any cause in the absence of progression), whichever occurs earlier. Kaplan-Meier estimates at 12 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. The Tumor Response-Evaluable Set includes all participants in the full analysis set with at least 1 evaluable postbaseline response assessment using RECIST 1.1. Only participants with data collected at Month 12 are reported. -9999 and 9999= The 95% confidence interval data was not determined as no participants with PFS at Month 12.

End point type	Secondary
----------------	-----------

End point timeframe:

12 months

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	0 ^[15]	3	6
Units: percentage of participants				
number (confidence interval 95%)	27.6 (6.9 to 53.9)	(to)	0.0 (-9999 to 9999)	16.7 (0.8 to 51.7)

Notes:

[15] - No participants analyzed.

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	9	72
Units: percentage of participants				
number (confidence interval 95%)	16.8 (2.7 to 41.2)	0.0 (-9999 to 9999)	12.5 (0.7 to 42.3)	26.2 (15.8 to 37.8)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Overall Survival (OS) at 2 Months

End point title	Monotherapy Only: Percentage of Participants With Overall Survival (OS) at 2 Months ^[16]
-----------------	---

End point description:

OS is defined as the time from the date of enrollment to the date of death from any cause. Kaplan-Meier estimates at 2 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. Full Analysis Set consisted of all participants who received ≥ 1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Secondary
----------------	-----------

End point timeframe:

2 months

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	98.7 (90.9 to 99.8)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Overall Survival at 4 Months

End point title	Monotherapy Only: Percentage of Participants With Overall Survival at 4 Months ^[17]
-----------------	--

End point description:

OS is defined as the time from the date of enrollment to the date of death from any cause. Kaplan-Meier estimates at 4 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. Full Analysis Set consisted of all participants who received ≥1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Secondary
----------------	-----------

End point timeframe:

4 months

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75

Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	90.0 (47.3 to 98.5)	97.3 (89.6 to 99.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Overall Survival at 6 Months

End point title	Monotherapy Only: Percentage of Participants With Overall Survival at 6 Months ^[18]
-----------------	--

End point description:

OS is defined as the time from the date of enrollment to the date of death from any cause. Kaplan-Meier estimates at 6 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. Full Analysis Set consisted of all participants who received ≥ 1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints

End point type	Secondary
----------------	-----------

End point timeframe:

6 months

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	90.0 (47.3 to 98.5)	97.3 (89.6 to 99.3)

Statistical analyses

Secondary: Monotherapy Only: Percentage of Participants With Overall Survival at 8 Months

End point title	Monotherapy Only: Percentage of Participants With Overall Survival at 8 Months ^[19]
-----------------	--

End point description:

OS is defined as the time from the date of enrollment to the date of death from any cause. Kaplan-Meier estimates at 8 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. Full Analysis Set consisted of all participants who received ≥ 1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Secondary
----------------	-----------

End point timeframe:

8 months

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	90.0 (47.3 to 98.5)	94.0 (84.8 to 97.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Overall Survival at 10 Months

End point title	Monotherapy Only: Percentage of Participants With Overall Survival at 10 Months ^[20]
-----------------	---

End point description:

OS is defined as the time from the date of enrollment to the date of death from any cause. Kaplan-Meier estimates at 10 months and their confidence intervals are calculated with the log-log transformation

methodology of Kalbfleisch and Prentice. Full Analysis Set consisted of all participants who received ≥ 1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Secondary
----------------	-----------

End point timeframe:

10 months

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	83.3 (27.3 to 97.5)

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	90.0 (47.3 to 98.5)	90.0 (78.8 to 95.4)

Statistical analyses

No statistical analyses for this end point

Secondary: Monotherapy Only: Percentage of Participants With Overall Survival at 12 Months

End point title	Monotherapy Only: Percentage of Participants With Overall Survival at 12 Months ^[21]
-----------------	---

End point description:

OS is defined as the time from the date of enrollment to the date of death from any cause. Kaplan-Meier estimates at 12 months and their confidence intervals are calculated with the log-log transformation methodology of Kalbfleisch and Prentice. Full Analysis Set consisted of all participants who received ≥ 1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Secondary
----------------	-----------

End point timeframe:

12 months

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	83.3 (27.3 to 97.5)

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: percentage of participants				
number (confidence interval 95%)	100.0 (100.0 to 100.0)	100.0 (100.0 to 100.0)	90.0 (47.3 to 98.5)	84.2 (69.8 to 92.1)

Statistical analyses

No statistical analyses for this end point

Secondary: Objective Response Rate (ORR) for ZN-c5 as a Monotherapy

End point title	Objective Response Rate (ORR) for ZN-c5 as a Monotherapy ^[22]
-----------------	--

End point description:

ORR is defined as the number of participants with measurable disease who have at least 1 confirmed response of CR or PR prior to any evidence of progression (as defined by RECIST v1.1). Full Analysis Set consisted of all participants who received ≥1 dose of study drug and was used in the analyses of participant characteristics and efficacy endpoints.

End point type	Secondary
----------------	-----------

End point timeframe:

24 weeks

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only reporting groups in which participants received monotherapy were evaluated for this end point.

End point values	Phase 1 (Monotherapy) : ZN-c5 50 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg QD	Phase 1 (Monotherapy) : ZN-c5 100 mg QD	Phase 1 (Monotherapy) : ZN-c5 75 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	3	3	6
Units: participants	0	0	0	0

End point values	Phase 1 (Monotherapy) : ZN-c5 150 mg QD	Phase 1 (Monotherapy) : ZN-c5 150 mg BID	Phase 1 (Monotherapy) : ZN-c5 300 mg QD	Phase 2 (Monotherapy) : ZN-c5 50 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	3	10	75
Units: participants	1	0	1	3

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

12 months

Adverse event reporting additional description:

For the safety analysis, Phase 1 Monotherapy group was combined with Phase 2 Monotherapy group.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

Reporting groups

Reporting group title	Phase 1 (Monotherapy): ZN-c5 50 mg QD
-----------------------	---------------------------------------

Reporting group description:

Participants who received ZN-c5 50 mg QD in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Monotherapy): ZN-c5 75 mg QD
-----------------------	---------------------------------------

Reporting group description:

Participants who received ZN-c5 75 mg QD in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Monotherapy): ZN-c5 100 mg QD
-----------------------	--

Reporting group description:

Participants who received ZN-c5 100 mg QD in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Monotherapy): ZN-c5 75 mg BID
-----------------------	--

Reporting group description:

Participants who received ZN-c5 75 mg BID in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Monotherapy): ZN-c5 150 mg QD
-----------------------	--

Reporting group description:

Participants who received ZN-c5 150 mg QD in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Monotherapy): ZN-c5 150 mg BID
-----------------------	---

Reporting group description:

Participants who received ZN-c5 150 mg BID in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Monotherapy): ZN-c5 300 mg QD
-----------------------	--

Reporting group description:

Participants who received ZN-c5 300 mg QD in Phase 1 were included in this arm.

Reporting group title	Phase 2 (Monotherapy): ZN-c5 50 mg QD
-----------------------	---------------------------------------

Reporting group description:

Participants who received ZN-c5 50 mg QD in Phase 2 were included in this arm.

Reporting group title	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
-----------------------	---

Reporting group description:

Participants who received ZN-c5 25 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib
-----------------------	--

Reporting group description:

Participants who received ZN-c5 25 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib
-----------------------	---

Reporting group description:

Participants who received ZN-c5 50 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.

Reporting group title	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
-----------------------	--

Reporting group description:

Participants who received ZN-c5 50 mg BID along with Palbociclib (IBRANCE®) in Phase 1 were included

in this arm.

Reporting group title	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib
Reporting group description:	
Participants who received ZN-c5 100 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	
Reporting group title	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib
Reporting group description:	
Participants who received ZN-c5 150 mg QD along with Palbociclib (IBRANCE®) in Phase 1 were included in this arm.	

Serious adverse events	Phase 1 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Monotherapy): ZN- c5 75 mg QD	Phase 1 (Monotherapy): ZN- c5 100 mg QD
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
number of deaths (all causes)	4	1	1
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac disorder			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 1 (Monotherapy): ZN- c5 75 mg BID	Phase 1 (Monotherapy): ZN- c5 150 mg QD	Phase 1 (Monotherapy): ZN- c5 150 mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 6 (16.67%)	2 / 15 (13.33%)	0 / 3 (0.00%)
number of deaths (all causes)	2	6	1
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Femur fracture			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Transient ischaemic attack			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Device related infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 1 (Monotherapy): ZN- c5 300 mg QD	Phase 2 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 10 (20.00%)	9 / 75 (12.00%)	4 / 10 (40.00%)
number of deaths (all causes)	4	8	2
number of deaths resulting from adverse events	0	1	0
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Cardiac disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	2 / 10 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	2 / 75 (2.67%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Musculoskeletal and connective tissue disorders	Arthralgia			
	subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
	Back pain			
	subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
Infections and infestations	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
	COVID-19			
	subjects affected / exposed	0 / 10 (0.00%)	2 / 75 (2.67%)	1 / 10 (10.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
	Cellulitis			
	subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
	Device related infection			
	subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
	occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
	Pneumonia			
	subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	1 / 10 (10.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 5 (20.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
number of deaths (all causes)	3	2	0
number of deaths resulting from adverse events	0	0	0

Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 12 (16.67%)	1 / 3 (33.33%)	
number of deaths (all causes)	4	1	
number of deaths resulting from adverse events	0	0	
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Embolism			

subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Cardiac disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Calculus urinary			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Phase 1 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Monotherapy): ZN- c5 75 mg QD	Phase 1 (Monotherapy): ZN- c5 100 mg QD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 16 (93.75%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cancer pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Endometrial cancer			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malignant pleural effusion			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Metastases to skin			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	1 / 16 (6.25%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Haematoma			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration			

site conditions			
Fatigue			
subjects affected / exposed	4 / 16 (25.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	4	1	0
Asthenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Chest pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Medical device site erythema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			

Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders			
Breast pain subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Vaginal discharge subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Breast necrosis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Pelvic pain subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Premature menopause subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Uterine haemorrhage subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vulva cyst subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vulvovaginal dryness subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vulvovaginal pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vulvovaginal pruritus			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 16 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Dyspnoea			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Rhinitis allergic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Acute respiratory failure			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Haemoptysis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hiccups			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mediastinal mass			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Pleural effusion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus disorder			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Affect lability			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Libido increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mania			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALT increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
AST increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
GGT increased			
subjects affected / exposed	3 / 16 (18.75%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Lymphocyte count decreased			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 16 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Platelet count decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 16 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood bicarbonate increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
CD4 lymphocytes decreased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Carbohydrate antigen 27.29 increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Carcinoembryonic antigen increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
International normalised ratio increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Low density lipoprotein increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Monocyte count decreased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tumour marker increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Breast injury			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rib fracture			
subjects affected / exposed	0 / 16 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Tooth injury			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Upper limb fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Arrhythmia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pericarditis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	2 / 16 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Tachycardia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Headache			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Anosmia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Carotid artery stenosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Memory impairment			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle spasticity			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Myoclonus			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Transient ischaemic attack			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Pancytopenia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Ear and labyrinth disorders			
Ear discomfort subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Ear pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Middle ear inflammation subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eye disorders			
Diplopia subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eyelid function disorder subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Photopsia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Uveitis			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual field defect			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	2 / 16 (12.50%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Stomatitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 16 (6.25%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Abdominal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Dry mouth			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Enterocolitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 16 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Frequent bowel movements			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oesophageal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			

Rash maculo-papular			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Blister			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertrichosis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Rash			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Rosacea			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Haematuria			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary retention			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Urinary tract pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Goitre subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 16 (12.50%) 2	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Back pain subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Myalgia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Pain in extremity subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Musculoskeletal chest pain			

subjects affected / exposed	0 / 16 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Arthritis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest wall mass			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle fatigue			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Plantar fasciitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sacral pain			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Nasopharyngitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vaginal infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypertriglyceridaemia			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 16 (0.00%)	2 / 3 (66.67%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Decreased appetite			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Hypoglycaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dehydration			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gout			

subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Phase 1 (Monotherapy): ZN- c5 75 mg BID	Phase 1 (Monotherapy): ZN- c5 150 mg QD	Phase 1 (Monotherapy): ZN- c5 150 mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)	14 / 15 (93.33%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Cancer pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Endometrial cancer			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malignant pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metastases to skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hot flush			
subjects affected / exposed	2 / 6 (33.33%)	3 / 15 (20.00%)	0 / 3 (0.00%)
occurrences (all)	2	3	0
Hypertension			
subjects affected / exposed	0 / 6 (0.00%)	4 / 15 (26.67%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
Hypotension			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Haematoma			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lymphoedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 6 (33.33%)	3 / 15 (20.00%)	1 / 3 (33.33%)
occurrences (all)	2	3	1
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Chest pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Medical device site erythema			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Non-cardiac chest pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders Breast pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0	1 / 3 (33.33%) 1
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	1 / 3 (33.33%) 1
Breast necrosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Pelvic pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Premature menopause subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Uterine haemorrhage subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Vulva cyst			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal dryness			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Dyspnoea			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Rhinitis allergic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Acute respiratory failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mediastinal mass			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Wheezing			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	2 / 6 (33.33%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Anxiety			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Affect lability			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Delirium			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Irritability			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Libido increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Mania			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALT increased			
subjects affected / exposed	1 / 6 (16.67%)	2 / 15 (13.33%)	1 / 3 (33.33%)
occurrences (all)	1	2	1
AST increased			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
Blood cholesterol increased			

subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Blood creatinine increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
GGT increased			
subjects affected / exposed	1 / 6 (16.67%)	3 / 15 (20.00%)	2 / 3 (66.67%)
occurrences (all)	1	3	2
Lymphocyte count decreased			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Neutrophil count decreased			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Platelet count decreased			
subjects affected / exposed	1 / 6 (16.67%)	2 / 15 (13.33%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
White blood cell count decreased			
subjects affected / exposed	1 / 6 (16.67%)	3 / 15 (20.00%)	1 / 3 (33.33%)
occurrences (all)	1	3	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood bicarbonate increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Blood phosphorus increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Blood urea increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
CD4 lymphocytes decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Carbohydrate antigen 27.29 increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	1 / 3 (33.33%) 1
Carcinoembryonic antigen increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	1 / 3 (33.33%) 1
International normalised ratio increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Low density lipoprotein increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Monocyte count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Tumour marker increased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Breast injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	2 / 6 (33.33%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Procedural pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rib fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Skin laceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tooth injury			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Upper limb fracture subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Wound subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Cardiac disorders			
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 15 (13.33%) 2	0 / 3 (0.00%) 0
Arrhythmia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Pericarditis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 15 (13.33%) 2	0 / 3 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	4 / 15 (26.67%) 4	1 / 3 (33.33%) 1
Anosmia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Carotid artery stenosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Muscle spasticity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Transient ischaemic attack			

subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)	3 / 15 (20.00%)	1 / 3 (33.33%)
occurrences (all)	1	3	1
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pancytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Middle ear inflammation			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Tinnitus			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry eye			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eyelid function disorder			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Photopsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Uveitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual field defect			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
Diarrhoea			
subjects affected / exposed	1 / 6 (16.67%)	3 / 15 (20.00%)	1 / 3 (33.33%)
occurrences (all)	1	3	1
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
Nausea			
subjects affected / exposed	2 / 6 (33.33%)	6 / 15 (40.00%)	2 / 3 (66.67%)
occurrences (all)	2	6	2
Stomatitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	3 / 15 (20.00%)	2 / 3 (66.67%)
occurrences (all)	0	3	2
Abdominal pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	2 / 3 (66.67%)
occurrences (all)	1	0	2
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Enterocolitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oesophageal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Oral pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertrichosis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Rosacea			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Micturition urgency subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Urinary retention subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Urinary tract pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Goitre subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	3 / 15 (20.00%) 3	1 / 3 (33.33%) 1
Back pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 15 (13.33%) 2	0 / 3 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 15 (13.33%) 2	0 / 3 (0.00%) 0
Bone pain			

subjects affected / exposed	1 / 6 (16.67%)	2 / 15 (13.33%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
Flank pain			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Muscle spasms			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	2 / 6 (33.33%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Arthritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest wall mass			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle fatigue			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Osteonecrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis of jaw			

subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Plantar fasciitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sacral pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	2 / 15 (13.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Catheter site infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Cystitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Diverticulitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Gastrointestinal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Otitis media			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vaginal infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	3 / 15 (20.00%) 3	1 / 3 (33.33%) 1
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 15 (13.33%) 2	1 / 3 (33.33%) 1
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 15 (13.33%) 2	1 / 3 (33.33%) 1
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 15 (6.67%) 1	0 / 3 (0.00%) 0
Hyponatraemia subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	2 / 15 (13.33%) 2	0 / 3 (0.00%) 0
Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	3 / 15 (20.00%) 3	1 / 3 (33.33%) 1
Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	1 / 3 (33.33%) 1
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 15 (0.00%) 0	0 / 3 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 15 (13.33%) 2	0 / 3 (0.00%) 0
Hypomagnesaemia			

subjects affected / exposed	0 / 6 (0.00%)	3 / 15 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Dehydration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gout			
subjects affected / exposed	0 / 6 (0.00%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hyperkalaemia			
subjects affected / exposed	1 / 6 (16.67%)	1 / 15 (6.67%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Hyperphosphataemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 15 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase 1 (Monotherapy): ZN- c5 300 mg QD	Phase 2 (Monotherapy): ZN- c5 50 mg QD	Phase 1 (Combination Therapy): ZNc5 25mg QD + Palbociclib
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	55 / 75 (73.33%)	10 / 10 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cancer pain			
subjects affected / exposed	1 / 10 (10.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Endometrial cancer			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Malignant pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Metastases to skin subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Vascular disorders			
Hot flush subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	2 / 75 (2.67%) 2	1 / 10 (10.00%) 1
Hypertension subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	3 / 75 (4.00%) 3	1 / 10 (10.00%) 1
Hypotension subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 75 (1.33%) 1	2 / 10 (20.00%) 2
Haematoma subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Lymphoedema subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	6 / 75 (8.00%) 6	5 / 10 (50.00%) 5
Asthenia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	7 / 75 (9.33%) 7	0 / 10 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 75 (2.67%) 2	0 / 10 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Chest pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	3 / 75 (4.00%) 3	0 / 10 (0.00%) 0
Chills			

subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Localised oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Medical device site erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	0 / 10 (0.00%)	2 / 75 (2.67%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Vaginal discharge			
subjects affected / exposed	0 / 10 (0.00%)	2 / 75 (2.67%)	1 / 10 (10.00%)
occurrences (all)	0	2	1
Breast necrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Premature menopause			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Uterine haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vulva cyst			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Vulvovaginal dryness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Dyspnoea			
subjects affected / exposed	1 / 10 (10.00%)	7 / 75 (9.33%)	2 / 10 (20.00%)
occurrences (all)	1	7	2
Oropharyngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Acute respiratory failure			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dysphonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Haemoptysis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Mediastinal mass			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	3 / 75 (4.00%)	1 / 10 (10.00%)
occurrences (all)	0	3	1
Pleuritic pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pneumothorax			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 75 (1.33%) 1	1 / 10 (10.00%) 1
Sinus disorder subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Anxiety subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Affect lability subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Delirium subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Irritability subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Libido increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Mania subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0

Investigations			
ALT increased			
subjects affected / exposed	2 / 10 (20.00%)	6 / 75 (8.00%)	2 / 10 (20.00%)
occurrences (all)	2	6	2
AST increased			
subjects affected / exposed	1 / 10 (10.00%)	7 / 75 (9.33%)	1 / 10 (10.00%)
occurrences (all)	1	7	1
Blood cholesterol increased			
subjects affected / exposed	1 / 10 (10.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Blood creatinine increased			
subjects affected / exposed	1 / 10 (10.00%)	6 / 75 (8.00%)	5 / 10 (50.00%)
occurrences (all)	1	6	5
GGT increased			
subjects affected / exposed	2 / 10 (20.00%)	11 / 75 (14.67%)	1 / 10 (10.00%)
occurrences (all)	2	11	1
Lymphocyte count decreased			
subjects affected / exposed	2 / 10 (20.00%)	3 / 75 (4.00%)	5 / 10 (50.00%)
occurrences (all)	2	3	5
Neutrophil count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	8 / 10 (80.00%)
occurrences (all)	0	0	8
Platelet count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
White blood cell count decreased			
subjects affected / exposed	1 / 10 (10.00%)	2 / 75 (2.67%)	7 / 10 (70.00%)
occurrences (all)	1	2	7
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 10 (0.00%)	7 / 75 (9.33%)	0 / 10 (0.00%)
occurrences (all)	0	7	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 10 (0.00%)	6 / 75 (8.00%)	0 / 10 (0.00%)
occurrences (all)	0	6	0
Weight decreased			

subjects affected / exposed	0 / 10 (0.00%)	4 / 75 (5.33%)	1 / 10 (10.00%)
occurrences (all)	0	4	1
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blood bicarbonate increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Blood bilirubin increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blood phosphorus increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
C-reactive protein increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
CD4 lymphocytes decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Carbohydrate antigen 27.29 increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Carcinoembryonic antigen increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
International normalised ratio increased			
subjects affected / exposed	0 / 10 (0.00%)	2 / 75 (2.67%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Low density lipoprotein increased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Monocyte count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Tumour marker increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Weight increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Breast injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	1 / 10 (10.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Rib fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Thermal burn			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tooth injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Upper limb fracture			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Wound			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	1 / 10 (10.00%)	3 / 75 (4.00%)	0 / 10 (0.00%)
occurrences (all)	1	3	0
Arrhythmia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Palpitations			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pericarditis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Sinus bradycardia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	1	1	0

Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	2 / 10 (20.00%)
occurrences (all)	0	1	2
Headache			
subjects affected / exposed	3 / 10 (30.00%)	3 / 75 (4.00%)	1 / 10 (10.00%)
occurrences (all)	3	3	1
Anosmia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Carotid artery stenosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Muscle spasticity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Peripheral sensory neuropathy			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Syncope subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Transient ischaemic attack subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	5 / 75 (6.67%) 5	5 / 10 (50.00%) 5
Neutropenia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	6 / 75 (8.00%) 6	0 / 10 (0.00%) 0
Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Pancytopenia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Ear and labyrinth disorders Ear discomfort subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Middle ear inflammation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Tinnitus			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Eye disorders			
Diplopia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Eyelid function disorder subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 75 (1.33%) 1	0 / 10 (0.00%) 0
Photopsia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Uveitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Vision blurred subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Visual field defect subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Gastrointestinal disorders			
Constipation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 75 (2.67%) 2	1 / 10 (10.00%) 1
Diarrhoea			

subjects affected / exposed	1 / 10 (10.00%)	7 / 75 (9.33%)	1 / 10 (10.00%)
occurrences (all)	1	7	1
Dyspepsia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	4 / 10 (40.00%)	6 / 75 (8.00%)	3 / 10 (30.00%)
occurrences (all)	4	6	3
Stomatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	2 / 10 (20.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Abdominal pain			
subjects affected / exposed	1 / 10 (10.00%)	4 / 75 (5.33%)	0 / 10 (0.00%)
occurrences (all)	1	4	0
Abdominal distension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Enterocolitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Lip swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oesophageal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	2 / 75 (2.67%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Hepatobiliary disorders			
Hepatic pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	3 / 10 (30.00%)
occurrences (all)	0	1	3
Alopecia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	2 / 10 (20.00%)
occurrences (all)	0	1	2
Blister			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Hyperhidrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hypertrichosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Onychoclasia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Skin mass			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dysuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Micturition urgency			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Nephrolithiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Goitre			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	2 / 10 (20.00%)	4 / 75 (5.33%)	0 / 10 (0.00%)
occurrences (all)	2	4	0
Back pain			
subjects affected / exposed	1 / 10 (10.00%)	5 / 75 (6.67%)	0 / 10 (0.00%)
occurrences (all)	1	5	0
Myalgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Bone pain			
subjects affected / exposed	0 / 10 (0.00%)	4 / 75 (5.33%)	1 / 10 (10.00%)
occurrences (all)	0	4	1
Flank pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Arthritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Chest wall mass			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Muscle fatigue			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Osteonecrosis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Osteonecrosis of jaw subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Pain in jaw subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 75 (1.33%) 1	0 / 10 (0.00%) 0
Plantar fasciitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Sacral pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Infections and infestations			
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	3 / 75 (4.00%) 3	3 / 10 (30.00%) 3
COVID-19 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	8 / 75 (10.67%) 8	1 / 10 (10.00%) 1
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Catheter site infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Conjunctivitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Diverticulitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Hordeolum			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	2 / 75 (2.67%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Otitis media			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 75 (1.33%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Rash pustular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sepsis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vaginal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 75 (0.00%)	3 / 10 (30.00%)
occurrences (all)	2	0	3
Hypertriglyceridaemia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 75 (0.00%)	2 / 10 (20.00%)
occurrences (all)	2	0	2
Hypoalbuminaemia			
subjects affected / exposed	2 / 10 (20.00%)	1 / 75 (1.33%)	2 / 10 (20.00%)
occurrences (all)	2	1	2
Hypocalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 75 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Hypokalaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 75 (0.00%)	5 / 10 (50.00%)
occurrences (all)	1	0	5
Hyponatraemia			
subjects affected / exposed	2 / 10 (20.00%)	1 / 75 (1.33%)	3 / 10 (30.00%)
occurrences (all)	2	1	3

Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	2 / 10 (20.00%) 2
Decreased appetite subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	4 / 75 (5.33%) 4	0 / 10 (0.00%) 0
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	3 / 75 (4.00%) 3	1 / 10 (10.00%) 1
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Hypomagnesaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 75 (1.33%) 1	0 / 10 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 75 (0.00%) 0	1 / 10 (10.00%) 1
Glucose tolerance impaired subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Gout subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 75 (2.67%) 2	0 / 10 (0.00%) 0
Hyperphosphataemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 75 (0.00%) 0	0 / 10 (0.00%) 0

Non-serious adverse events	Phase 1 (Combination Therapy): ZNc5 25mg BID + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 50mg BID + Palbociclib
Total subjects affected by non-serious adverse events subjects affected / exposed	5 / 5 (100.00%)	18 / 18 (100.00%)	2 / 2 (100.00%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Cancer pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Endometrial cancer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Malignant pleural effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Metastases to skin			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hot flush			
subjects affected / exposed	1 / 5 (20.00%)	4 / 18 (22.22%)	1 / 2 (50.00%)
occurrences (all)	1	4	1
Hypertension			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hypotension			
subjects affected / exposed	0 / 5 (0.00%)	3 / 18 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 5 (40.00%)	10 / 18 (55.56%)	0 / 2 (0.00%)
occurrences (all)	2	10	0

Asthenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Localised oedema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Malaise			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Medical device site erythema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	1 / 5 (20.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Breast pain			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Vaginal discharge			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Breast necrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Premature menopause			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Uterine haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vulva cyst			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal dryness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	1 / 5 (20.00%)	4 / 18 (22.22%)	1 / 2 (50.00%)
occurrences (all)	1	4	1
Dyspnoea			
subjects affected / exposed	1 / 5 (20.00%)	3 / 18 (16.67%)	0 / 2 (0.00%)
occurrences (all)	1	3	0
Oropharyngeal pain			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	1 / 2 (50.00%)
occurrences (all)	0	2	1
Rhinitis allergic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Acute respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Haemoptysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Mediastinal mass			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Pleuritic pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pneumonitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pulmonary embolism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Sinus disorder			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 5 (0.00%)	6 / 18 (33.33%)	1 / 2 (50.00%)
occurrences (all)	0	6	1
Anxiety			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Affect lability			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Delirium			

subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Libido increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Mania			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALT increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	1 / 2 (50.00%)
occurrences (all)	1	0	1
AST increased			
subjects affected / exposed	2 / 5 (40.00%)	4 / 18 (22.22%)	0 / 2 (0.00%)
occurrences (all)	2	4	0
Blood cholesterol increased			
subjects affected / exposed	2 / 5 (40.00%)	4 / 18 (22.22%)	0 / 2 (0.00%)
occurrences (all)	2	4	0
Blood creatinine increased			
subjects affected / exposed	1 / 5 (20.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
GGT increased			
subjects affected / exposed	1 / 5 (20.00%)	1 / 18 (5.56%)	1 / 2 (50.00%)
occurrences (all)	1	1	1
Lymphocyte count decreased			
subjects affected / exposed	1 / 5 (20.00%)	6 / 18 (33.33%)	1 / 2 (50.00%)
occurrences (all)	1	6	1
Neutrophil count decreased			
subjects affected / exposed	3 / 5 (60.00%)	14 / 18 (77.78%)	1 / 2 (50.00%)
occurrences (all)	3	14	1

Platelet count decreased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	5 / 18 (27.78%) 5	0 / 2 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3	14 / 18 (77.78%) 14	1 / 2 (50.00%) 1
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 18 (11.11%) 2	0 / 2 (0.00%) 0
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 18 (0.00%) 0	0 / 2 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 18 (5.56%) 1	0 / 2 (0.00%) 0
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 18 (5.56%) 1	0 / 2 (0.00%) 0
Blood bicarbonate increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 18 (0.00%) 0	0 / 2 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 18 (0.00%) 0	0 / 2 (0.00%) 0
Blood phosphorus increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 18 (5.56%) 1	0 / 2 (0.00%) 0
Blood urea increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 18 (0.00%) 0	0 / 2 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 18 (0.00%) 0	0 / 2 (0.00%) 0
CD4 lymphocytes decreased			

subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Carbohydrate antigen 27.29 increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Carcinoembryonic antigen increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Low density lipoprotein increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Monocyte count decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Platelet count increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tumour marker increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Breast injury			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Eye contusion			

subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Rib fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tooth injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Upper limb fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Arrhythmia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Palpitations			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Pericarditis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 5 (0.00%)	3 / 18 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Headache			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Anosmia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Carotid artery stenosis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dysgeusia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hyperaesthesia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Muscle spasticity			

subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Transient ischaemic attack			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 5 (40.00%)	12 / 18 (66.67%)	1 / 2 (50.00%)
occurrences (all)	2	12	1
Neutropenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Pancytopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	1 / 5 (20.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Middle ear inflammation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Eyelid function disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Photopsia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Uveitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vision blurred			

subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Visual field defect			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 5 (20.00%)	4 / 18 (22.22%)	0 / 2 (0.00%)
occurrences (all)	1	4	0
Diarrhoea			
subjects affected / exposed	2 / 5 (40.00%)	3 / 18 (16.67%)	0 / 2 (0.00%)
occurrences (all)	2	3	0
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	4 / 18 (22.22%)	0 / 2 (0.00%)
occurrences (all)	0	4	0
Nausea			
subjects affected / exposed	3 / 5 (60.00%)	6 / 18 (33.33%)	0 / 2 (0.00%)
occurrences (all)	3	6	0
Stomatitis			
subjects affected / exposed	1 / 5 (20.00%)	3 / 18 (16.67%)	0 / 2 (0.00%)
occurrences (all)	1	3	0
Vomiting			
subjects affected / exposed	1 / 5 (20.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Enterocolitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Lip swelling			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Oesophageal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hepatic pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Alopecia			

subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Pruritus			
subjects affected / exposed	2 / 5 (40.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	2	0	0
Blister			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dermatitis acneiform			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Hypertrichosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Psoriasis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Rosacea			

subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dysuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Urinary incontinence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Urinary tract pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Goitre			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 5 (40.00%)	9 / 18 (50.00%)	0 / 2 (0.00%)
occurrences (all)	2	9	0
Back pain			
subjects affected / exposed	2 / 5 (40.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	2	2	0
Myalgia			
subjects affected / exposed	0 / 5 (0.00%)	4 / 18 (22.22%)	0 / 2 (0.00%)
occurrences (all)	0	4	0
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	3 / 18 (16.67%)	0 / 2 (0.00%)
occurrences (all)	0	3	0
Bone pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Muscle spasms			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Chest wall mass			

subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Muscle fatigue			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	1 / 5 (20.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Musculoskeletal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Osteonecrosis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Pain in jaw			
subjects affected / exposed	1 / 5 (20.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Plantar fasciitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Sacral pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0

COVID-19			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Catheter site infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0

Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	1 / 2 (50.00%)
occurrences (all)	0	0	1
Skin infection			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Tooth infection			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Vaginal infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 5 (20.00%)	3 / 18 (16.67%)	1 / 2 (50.00%)
occurrences (all)	1	3	1
Hypertriglyceridaemia			
subjects affected / exposed	1 / 5 (20.00%)	5 / 18 (27.78%)	0 / 2 (0.00%)
occurrences (all)	1	5	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	0	2	0
Hypocalcaemia			

subjects affected / exposed	0 / 5 (0.00%)	4 / 18 (22.22%)	0 / 2 (0.00%)
occurrences (all)	0	4	0
Hypokalaemia			
subjects affected / exposed	0 / 5 (0.00%)	4 / 18 (22.22%)	0 / 2 (0.00%)
occurrences (all)	0	4	0
Hyponatraemia			
subjects affected / exposed	1 / 5 (20.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
Hypophosphataemia			
subjects affected / exposed	0 / 5 (0.00%)	4 / 18 (22.22%)	1 / 2 (50.00%)
occurrences (all)	0	4	1
Decreased appetite			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hypercalcaemia			
subjects affected / exposed	1 / 5 (20.00%)	2 / 18 (11.11%)	0 / 2 (0.00%)
occurrences (all)	1	2	0
Hypoglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Hypomagnesaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Dehydration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Gout			
subjects affected / exposed	0 / 5 (0.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	1 / 5 (20.00%)	1 / 18 (5.56%)	0 / 2 (0.00%)
occurrences (all)	1	1	0
Hyperphosphataemia			

subjects affected / exposed	1 / 5 (20.00%)	0 / 18 (0.00%)	0 / 2 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Phase 1 (Combination Therapy): ZNc5 100mg QD + Palbociclib	Phase 1 (Combination Therapy): ZNc5 150mg QD + Palbociclib	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 12 (100.00%)	3 / 3 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Cancer pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Endometrial cancer			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Malignant pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Metastases to skin			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Hypertension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hypotension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Haematoma			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Lymphoedema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 12 (25.00%)	2 / 3 (66.67%)	
occurrences (all)	3	2	
Asthenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Oedema peripheral			
subjects affected / exposed	2 / 12 (16.67%)	1 / 3 (33.33%)	
occurrences (all)	2	1	
Pyrexia			
subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)	
occurrences (all)	2	0	
Chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Chills			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Localised oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Malaise			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Medical device site erythema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Non-cardiac chest pain			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Reproductive system and breast disorders Breast pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Breast necrosis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 3 (0.00%) 0	
Pelvic pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Premature menopause subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Uterine haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Vulva cyst subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Vulvovaginal dryness			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Vulvovaginal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Vulvovaginal pruritus			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Dyspnoea			
subjects affected / exposed	2 / 12 (16.67%)	1 / 3 (33.33%)	
occurrences (all)	2	1	
Oropharyngeal pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Rhinitis allergic			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Acute respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Dysphonia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Epistaxis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Haemoptysis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hiccups			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Mediastinal mass			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Nasal congestion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Pleuritic pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Pneumonitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Pneumothorax			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Productive cough			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Sinus disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Upper-airway cough syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Wheezing			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			

Insomnia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 3 (33.33%)	
occurrences (all)	1	1	
Anxiety			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Affect lability			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Delirium			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Depression			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Irritability			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Libido increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Mania			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Investigations			
ALT increased			
subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)	
occurrences (all)	2	0	
AST increased			
subjects affected / exposed	2 / 12 (16.67%)	1 / 3 (33.33%)	
occurrences (all)	2	1	
Blood cholesterol increased			
subjects affected / exposed	2 / 12 (16.67%)	1 / 3 (33.33%)	
occurrences (all)	2	1	
Blood creatinine increased			

subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)
occurrences (all)	2	0
GGT increased		
subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)
occurrences (all)	2	0
Lymphocyte count decreased		
subjects affected / exposed	3 / 12 (25.00%)	2 / 3 (66.67%)
occurrences (all)	3	2
Neutrophil count decreased		
subjects affected / exposed	7 / 12 (58.33%)	3 / 3 (100.00%)
occurrences (all)	7	3
Platelet count decreased		
subjects affected / exposed	4 / 12 (33.33%)	1 / 3 (33.33%)
occurrences (all)	4	1
White blood cell count decreased		
subjects affected / exposed	11 / 12 (91.67%)	2 / 3 (66.67%)
occurrences (all)	11	2
Blood alkaline phosphatase increased		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Electrocardiogram QT prolonged		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Weight decreased		
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)
occurrences (all)	1	0
Activated partial thromboplastin time prolonged		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Blood bicarbonate increased		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Blood bilirubin increased		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0

Blood phosphorus increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Blood urea increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
CD4 lymphocytes decreased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 3 (0.00%) 0	
Carbohydrate antigen 27.29 increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Carcinoembryonic antigen increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
International normalised ratio increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Low density lipoprotein increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Monocyte count decreased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Platelet count increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Tumour marker increased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 3 (0.00%) 0	
Weight increased			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Breast injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Eye contusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Fall			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Procedural pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Rib fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Skin abrasion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Skin laceration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Thermal burn			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Tooth injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Upper limb fracture			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Wound subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Arrhythmia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Palpitations subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Pericarditis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Tachycardia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 3	1 / 3 (33.33%) 1	
Anosmia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Carotid artery stenosis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Dysgeusia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hyperaesthesia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Memory impairment			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Muscle spasticity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Myoclonus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Neuropathy peripheral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Paraesthesia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Sciatica			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Syncope			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Transient ischaemic attack			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	5 / 12 (41.67%)	2 / 3 (66.67%)	
occurrences (all)	5	2	
Neutropenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Lymphadenopathy			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Pancytopenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Ear pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Middle ear inflammation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Tinnitus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Vertigo			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Dry eye			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Eyelid function disorder			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Ocular hyperaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Photopsia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Uveitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Vision blurred			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Visual field defect			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 12 (8.33%)	1 / 3 (33.33%)	
occurrences (all)	1	1	
Diarrhoea			
subjects affected / exposed	2 / 12 (16.67%)	1 / 3 (33.33%)	
occurrences (all)	2	1	
Dyspepsia			
subjects affected / exposed	4 / 12 (33.33%)	1 / 3 (33.33%)	
occurrences (all)	4	1	
Nausea			
subjects affected / exposed	4 / 12 (33.33%)	2 / 3 (66.67%)	
occurrences (all)	4	2	
Stomatitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	

Abdominal pain		
subjects affected / exposed	1 / 12 (8.33%)	1 / 3 (33.33%)
occurrences (all)	1	1
Abdominal distension		
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	1
Abdominal pain upper		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Dry mouth		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Enterocolitis		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Flatulence		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Frequent bowel movements		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Lip swelling		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Mouth ulceration		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Oesophageal pain		
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)
occurrences (all)	1	0
Oral pain		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0

Toothache subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Hepatobiliary disorders Hepatic pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Skin and subcutaneous tissue disorders Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	2 / 3 (66.67%) 2	
Alopecia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 3 (0.00%) 0	
Pruritus subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Blister subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Dermatitis acneiform subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 3 (0.00%) 0	
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Dry skin subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Hyperhidrosis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Hypertrichosis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Night sweats			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Onychoclasia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Psoriasis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Rosacea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Skin hyperpigmentation			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Skin lesion			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Skin mass			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Dysuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Haematuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Micturition urgency			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	

Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Urinary retention subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Urinary tract pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Goitre subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	4 / 12 (33.33%) 4	1 / 3 (33.33%) 1	
Back pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Myalgia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 3 (33.33%) 1	
Pain in extremity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 3 (0.00%) 0	
Bone pain subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 3 (0.00%) 0	
Flank pain			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Muscle spasms		
subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)
occurrences (all)	2	0
Musculoskeletal chest pain		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Arthritis		
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	1
Chest wall mass		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Muscle fatigue		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Muscular weakness		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Musculoskeletal pain		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Musculoskeletal stiffness		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Neck pain		
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)
occurrences (all)	1	0
Osteonecrosis		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Osteonecrosis of jaw		
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0
Pain in jaw		

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Plantar fasciitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Sacral pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
COVID-19			
subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)	
occurrences (all)	2	0	
Upper respiratory tract infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Catheter site infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Cellulitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Conjunctivitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Cystitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Device related infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Diverticulitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	

Gastrointestinal infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hordeolum			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Otitis media			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Pneumonia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Rash pustular			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Sepsis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Sinusitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Skin infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Tooth infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Vaginal infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	

Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	5 / 12 (41.67%)	0 / 3 (0.00%)	
occurrences (all)	5	0	
Hypertriglyceridaemia			
subjects affected / exposed	3 / 12 (25.00%)	0 / 3 (0.00%)	
occurrences (all)	3	0	
Hypoalbuminaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hypokalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hyponatraemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Hypophosphataemia			
subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)	
occurrences (all)	2	0	
Decreased appetite			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Hypercalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hypoglycaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hypomagnesaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Dehydration			

subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Glucose tolerance impaired			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Gout			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hyperkalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Hyperphosphataemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 April 2018	EudraCT number added and investigator prompt removed from title page.
12 July 2018	The language throughout the protocol clarified, updated and streamlined to improve flow and readability.
25 June 2019	The study design updated.
14 February 2020	The study design updated.
14 September 2020	The study design updated.
20 April 2021	The clarification for Phase 2 assessment, food intake and abbreviated Pharmacokinetic sampling updated.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

In the Phase 2 Monotherapy efficacy analysis, efficacy was to be determined by the CBR, combining results with similar treatment groups. Phase 1 Monotherapy group was combined with Phase 2 Monotherapy group. Phase 2 Combination part was not initiated

Notes: